Page updated ·next FDA decision on the calendar·Data as of Oct 16, 2026 12:20 PM ET
No FDA decision on a tracked application has been published today, October 16, 2026. The most recent was RHHBY's Enspryng (satralizumab) (Approved) on October 15, 2026. Decisions from the past week and the next scheduled dates are below.
Original NDA/BLA approvals and new-indication supplements recorded in Drugs@FDA (openFDA) that are not goal dates on our calendar, by the FDA's own action date. openFDA posts records a few days after the action, and CBER products (vaccines, cell and gene therapies) are not in Drugs@FDA.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.